

Form PTO-1449 (modified)

Atty. Docket No.

ARCD:390US

Serial No.

10/782,401

List of Patents and Publications for Applicant's

Applicant

Philip Ashton-Rickardt

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

February 19, 2004

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C1	Al-Khunaizi <i>et al.</i> , "The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases," <i>Biochemistry</i> , 41:3189-3199, 2002.
	C2	Borner and Monney, "Apoptosis without caspases: an inefficient molecular guillotine?" <i>Cell Death Diff.</i> , 6:497-507, 1999.
	C3	Cooley <i>et al.</i> , "The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites," <i>Biochemistry</i> , 40(51):15762-15770, 2001.
	C4	Ferri and Kroemer, "Organelle-specific initiation of cell death pathways," <i>Nat. Cell Biol.</i> , 3:E255-E263, 2001.
	C5	Foghsgaard <i>et al.</i> , "Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor," <i>J. Cell. Biol.</i> , 153(5):999-1009, 2001.
	C6	Goossens <i>et al.</i> , "Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity," <i>Proc. Natl. Acad. Sci., USA</i> , 92:8115-8119, 1995.
↓	C7	Guicciardi <i>et al.</i> , "Cathepsin B contributes to TNF- $\alpha$ -mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c," <i>J. Clin. Invest.</i> , 106(9):1127-1137, 2000.
BF	C8	Hampson <i>et al.</i> , "Identification of a serpin specifically expressed in multipotent and bipotent hematopoietic progenitor cells and in activated T cells," <i>Blood</i> , 89(1):108-118, 1997.

25400625.1

EXAMINER:

/Brandon Fetterolf/

DATE CONSIDERED:

09/20/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. ARCD:390US	Serial No. 10/782,401
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Philip Ashton-Rickardt	
		Filing Date: February 19, 2004	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C9	Hampson <i>et al.</i> , "A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells," <i>Hematol. J.</i> , 2:150-160, 2001.
	C10	Inglis <i>et al.</i> , "Isolation of two cDNAs encoding novel $\alpha$ 1-antichymotrypsin-like proteins in a murine chondrocytic cell," <i>Gene</i> , 106(2):213-220, 1991.
	C11	Liu <i>et al.</i> , "NF- $\kappa$ B protects from the lysosomal pathway of cell death," <i>EMBO J.</i> , 22(19):5313-5322, 2003.
	C12	Morris <i>et al.</i> , "Murine serpin 2A is a redox-sensitive intracellular protein," <i>Biochem. J.</i> , 371(Pt 1):165-173, 2003.
↓	C13	Silverman <i>et al.</i> , "The serpins are an expanding superfamily of structurally similar but functionally diverse proteins," <i>J. Biol. Chem.</i> , 276(36):33293-33296, 2001.
BF	C14	Wyllie <i>et al.</i> , "Cell death: the significance of apoptosis," <i>Int. Rev. Cytol.</i> , 68:251-305, 1981.

25400625.1

EXAMINER: /Brandon Fetterolf/

DATE CONSIDERED: 09/20/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
ARCD:390USSerial No.  
10/782,401

List of Patents and Publications for Applicant's

Applicant  
Philip Ashton-Rickardt

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
February 19, 2004Group:  
1642U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
BF	A1	2004/0214773	10/28/04	Ashton-Rickardt	12	514	02/19/04

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
BF	B1	WO 99/57273	11/11/99	WIPO			YES

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C15	Bird, "Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins", <i>Immunology and Cell Biology</i> , 77: 47-57, 1999.
	C16	Guicciardi <i>et al.</i> , "Lysosomes in cell death.", <i>Oncogene</i> , 23:2881-2890, 2004.
	C17	Hamerman <i>et al.</i> , "Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog", <i>Journal of Immunology</i> , 168:2415-2423, 2002.
	C18	Liu <i>et al.</i> , "Induction of a cathepsin B inhibitor by NF-kB blocks the lysosomal pathway of cell death", <i>FASEB Journal</i> , 17: C152, 2003.
	C19	Liu <i>et al.</i> , "Serine protease inhibitor 2A inhibits caspase-independent cell death", <i>FEBS</i> , 569:49-53, 2004.
BF	C20	Morris <i>et al.</i> , "Nuclear localisation of haemopoietic serpin 2A: A potential regulatory of apoptosis", <i>British Journal of Haematology</i> , 101:27, 1998.

25621161.1

EXAMINER: /Brandon Fetterolf/

DATE CONSIDERED: 09/20/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)